WO2008008513A3 - Combination treatments - Google Patents

Combination treatments Download PDF

Info

Publication number
WO2008008513A3
WO2008008513A3 PCT/US2007/016032 US2007016032W WO2008008513A3 WO 2008008513 A3 WO2008008513 A3 WO 2008008513A3 US 2007016032 W US2007016032 W US 2007016032W WO 2008008513 A3 WO2008008513 A3 WO 2008008513A3
Authority
WO
WIPO (PCT)
Prior art keywords
combination treatments
combination
heme
biliverdin
disorders
Prior art date
Application number
PCT/US2007/016032
Other languages
French (fr)
Other versions
WO2008008513A2 (en
Inventor
Fritz H Bach
Arvand Haschemi
Leo E Otterbein
Original Assignee
Beth Israel Hospital
Fritz H Bach
Arvand Haschemi
Leo E Otterbein
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Hospital, Fritz H Bach, Arvand Haschemi, Leo E Otterbein filed Critical Beth Israel Hospital
Publication of WO2008008513A2 publication Critical patent/WO2008008513A2/en
Publication of WO2008008513A3 publication Critical patent/WO2008008513A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/25—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to the treatment of disorders using pharmaceutical agents in combination with heme oxygenase- 1 and/or heme degradation products, such as biliverdin or carbon monoxide.
PCT/US2007/016032 2006-07-13 2007-07-12 Combination treatments WO2008008513A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83048006P 2006-07-13 2006-07-13
US60/830,480 2006-07-13

Publications (2)

Publication Number Publication Date
WO2008008513A2 WO2008008513A2 (en) 2008-01-17
WO2008008513A3 true WO2008008513A3 (en) 2008-03-06

Family

ID=38749138

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/016032 WO2008008513A2 (en) 2006-07-13 2007-07-12 Combination treatments

Country Status (1)

Country Link
WO (1) WO2008008513A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110585215B (en) * 2019-09-19 2023-06-02 中山大学 New application of hemin and its complex in medicine
CN113289074A (en) * 2020-02-24 2021-08-24 张建强 Novel drug-coated stent and preparation method thereof
CN115105521B (en) * 2021-03-18 2023-10-03 天津医科大学 Use of adenosine or adenosine analogues in the preparation of a medicament for the prevention and/or treatment of necrotizing enterocolitis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003088748A1 (en) * 2002-04-15 2003-10-30 Beth Israel Deaconess Medical Center Use of heme oxygenase-1 and products of heme degradation
WO2004000368A1 (en) * 2002-06-21 2003-12-31 University Of Pittsburgh Of The Commonwealth System Of Higher Education Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003088748A1 (en) * 2002-04-15 2003-10-30 Beth Israel Deaconess Medical Center Use of heme oxygenase-1 and products of heme degradation
WO2004000368A1 (en) * 2002-06-21 2003-12-31 University Of Pittsburgh Of The Commonwealth System Of Higher Education Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BERBERAT PASCAL O ET AL: "Heme oxygenase-1-generated biliverdin ameliorates experimental murine colitis.", INFLAMMATORY BOWEL DISEASES APR 2005, vol. 11, no. 4, April 2005 (2005-04-01), pages 350 - 359, XP002461156, ISSN: 1078-0998 *
CATERINA DE R ET AL: "NITRIC OXIDE DECREASES CYTOKINE-INDUCED ENDOTHELIAL ACTIVATION NITRIC OXIDE SELECTIVELY REDUCES ENDOTHELIAL EXPRESSION OF ADHESION MOLECULES AND PROINFLAMMATORY CYTOKINES", JOURNAL OF CLINICAL INVESTIGATION, NEW YORK, NY, US, vol. 96, no. 1, July 1995 (1995-07-01), pages 60 - 68, XP001203633, ISSN: 0021-9738 *
CRONSTEIN B N: "ADENOSINE, AN ENDOGENOUS ANTI-INFLAMMATORY AGENT", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, WILLIAMS AND WILKINS, BALTIMORE, MD, US, vol. 76, no. 1, 1994, pages 5 - 13, XP009013003, ISSN: 1046-6673 *
HASCHEMI ARVAND ET AL: "Cross-regulation of carbon monoxide and the adenosine A2a receptor in macrophages", JOURNAL OF IMMUNOLOGY, vol. 178, no. 9, May 2007 (2007-05-01), pages 5921 - 5929, XP002461157, ISSN: 0022-1767 *
OTTERBEIN L E ET AL: "Heme oxygenase-1: unleashing the protective properties of heme", TRENDS IN IMMUNOLOGY, ELSEVIER, RAHWAY, NJ, US, vol. 24, no. 8, August 2003 (2003-08-01), pages 449 - 455, XP004442684, ISSN: 1471-4906 *
SULLIVAN G W: "ADENOSINE A2A RECEPTOR AGONISTS AS ANTI-INFLAMMATORY AGENTS", CURRENT OPINION IN INVESTIGATIONAL DRUGS, PHARMAPRESS, US, vol. 4, no. 11, November 2003 (2003-11-01), pages 1313 - 1319, XP009058611, ISSN: 1472-4472 *
VRAUX LE V ET AL: "INHIBITION OF HUMAN MONOCYTE TNF PRODUCTION BY ADENOSINE RECEPTOR AGONISTS", LIFE SCIENCES, PERGAMON PRESS, OXFORD, GB, vol. 52, no. 24, 1993, pages 1917 - 1924, XP000974191, ISSN: 0024-3205 *

Also Published As

Publication number Publication date
WO2008008513A2 (en) 2008-01-17

Similar Documents

Publication Publication Date Title
WO2008122049A3 (en) Methods and compositions for reduction of side effects of therapeutic treatments
WO2009020802A3 (en) Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity
EP2217596B8 (en) Bicyclic heterocycle derivatives and their use as modulators of the activity of gpr119
WO2006012642A3 (en) Pyrrole derivatives as pharmaceutical agents
TW200745124A (en) Azepinoindole derivatives as pharmaceutical agents
GB2442915B (en) Perylenequinone derivatives and uses thereof
WO2009044173A3 (en) Methods of treating cancer using notch pathway inhibitors
MX2007010560A (en) Roflumilast for the treatment of diabetes mellitus.
WO2006068729A3 (en) Methods and compositions for enhancing iron absorption
MX2009006536A (en) Organic compounds and their uses.
WO2009089494A3 (en) Pharmaceutical compositions
WO2007011962A3 (en) Treatment of cancer
WO2007074406A3 (en) Formulations for treatment of lipoprotein abnormalities comprising a statin a statin and a methylnicotinamide derivative
WO2008030883A3 (en) Treatment of cancer
TNSN08400A1 (en) Organic compounds and their uses
WO2007146983A3 (en) Compositions comprising tegaserod alone or in combination with a proton pump inhibitor for treating or preventing gastric injury
WO2007106537A3 (en) Aminoquinolones as gsk-3 inhibitors
WO2006116221A3 (en) Therapeutic combinations for the treatment or prevention of psychotic disorders
WO2008150530A3 (en) Cripto binding molecules
WO2010088450A3 (en) Arylamide derivatives useful in the treatment of diseases associated with serca activity
WO2006020680A3 (en) Heterocyclic compounds as pharmaceutical agents
WO2007103540A3 (en) Combination therapy with non-selective cox inhibitors to prevent cox-related gastric injuries
EP1879591B8 (en) Use of azapaullones for preventing and treating pancreatic autoimmune disorders
WO2008033440A3 (en) Treatment of hyperproliferative diseases with anthraquinones
WO2009071689A3 (en) 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07810469

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07810469

Country of ref document: EP

Kind code of ref document: A2